From the Research
Delta Sleep-Inducing Peptide (DSIP) is better absorbed orally than sublingually, as evidenced by a study showing that DSIP can be absorbed through the gastrointestinal tract into the systemic circulation 1. When considering the absorption of DSIP, it's crucial to evaluate the available routes of administration. While sublingual administration is often preferred for peptides due to its potential for bypassing first-pass metabolism, the specific case of DSIP absorption is supported by research indicating oral absorption is feasible.
Key Points to Consider:
- The study from 1983 1 demonstrates that DSIP can be absorbed through the GI tract, suggesting oral administration may not be as ineffective as initially thought for peptide absorption.
- Other routes like sublingual, intranasal, or injectable forms are generally preferred for therapeutic effectiveness of peptides due to their large molecular structure and vulnerability to degradation.
- The effectiveness of DSIP absorption orally is highlighted by the fact that significant increases in plasma DSIP-like immunoreactivity occurred after the feeding of a certain dose of DSIP analog, indicating absorption into the systemic circulation.
Administration Considerations:
- For oral use, the dosage and form of DSIP (e.g., encapsulated or liquid) can impact its absorption and effectiveness.
- Sublingual administration, while potentially beneficial for rapid absorption, may not offer a significant advantage over oral administration for DSIP, given the evidence supporting oral absorption.
Clinical Implications:
- The choice between oral and sublingual administration of DSIP should be based on individual patient factors, including tolerance, preference, and the specific clinical context.
- Healthcare providers should consider the most recent and highest quality evidence when making recommendations for DSIP administration, weighing the potential benefits and drawbacks of each route.